RELATIONSHIP BETWEEN INFLAMMATORY BOWEL DISEASE AND CHOLELITHIASIS
Main Article Content
Keywords
Inflammatory bowel diseases, Crohn's disease, ulcerative colitis, cholelithiasis
Abstract
This review study was conducted to investigate the association between inflammatory bowel disease (IBD) and the development of cholelithiasis at Liaquat University of Medical and Health Sciences Jamshoro Pakistan in the duration from November, 2023 to April, 2024. Individuals with IBD, particularly those with Crohn's disease, may have an elevated risk of developing gallstones compared to the general population. Ulcerative colitis and Crohn's disease are both classified as inflammatory bowel diseases (IBD), which are chronic inflammatory disorders affecting the gastrointestinal tract. Studies have suggested that the risk of gallstones may be more prominent in individuals with Crohn's disease compared to ulcerative colitis. Researchers are still working that how different types of Inflammatory Bowel Disease (IBD) might be connected to the formation of gallstones. Gallstones are hard particles that can form in the gallbladder. The relationship between these digestive conditions is not completely clear, and studies have given different and sometimes unclear results. In other words, scientists are still working to understand how IBD and gallstones might be linked, and there's no clear answer just yet.
References
1. Littlefield A, Lenahan C. Cholelithiasis: Presentation and management. Journal of midwifery & women's health. 2019;64(3):289-97.
2. Chen C-H, Lin C-L, Kao C-H. Association between inflammatory bowel disease and cholelithiasis: a nationwide population-based cohort study. International journal of environmental research and public health. 2018;15(3):513.
3. Fagagnini S, Heinrich H, Rossel J-B, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PloS one. 2017;12(10):e0185193.
4. da Silva Gaspar SR, Mendonca T, Oliveira P, Oliveira T, Dias J, Lopes T. Urolithiasis and crohn's disease. Urology annals. 2016;8(3):297.
5. Hegyi P, Maléth J, Walters JR, Hofmann AF, Keely SJ. Guts and gall: bile acids in regulation of intestinal epithelial function in health and disease. Physiological reviews. 2018;98(4):1983-2023.
6. Pereira S, Bain I, Kumar D, Dowling R. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Alimentary pharmacology & therapeutics. 2003;17(7):923-33.
7. Ramos GP, Papadakis KA, editors. Mechanisms of disease: inflammatory bowel diseases. Mayo Clinic Proceedings; 2019: Elsevier.
8. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129(3):827-36.
9. Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Tysk C, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013:gutjnl-2012-303661.
10. KHAN R, PARI B. RISK FACTORS OF GALLBLADDER STONE IN LADY READING HOSPITAL PESHAWAR, PAKISTAN. Quantum Journal of Social Sciences and Humanities. 2023;4(5):195-213.
11. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut and liver. 2012;6(2):172.
12. Krawczyk M, Miquel JF, Stokes CS, Zuniga S, Hampe J, Mittal B, et al. Genetics of biliary lithiasis from an ethnic perspective. Clinics and research in hepatology and gastroenterology. 2013;37(2):119-25.
13. Naeem M, Rahimnajjad NA, Rahimnajjad MK, Khurshid M, Ahmed QJ, Shahid SM, et al. Assessment of characteristics of patients with cholelithiasis from economically deprived rural Karachi, Pakistan. BMC research notes. 2012;5(1):1-8.
14. Aslam HM, Saleem S, Edhi MM, Shaikh HA, Hafiz M, Saleem M. Assessment of gallstone predictor: comparative analysis of ultrasonographic and biochemical parameters. International archives of medicine. 2013;6(1):1-7.
15. Geboes K. Histopathology of Crohn’s disease and ulcerative colitis. Inflammatory bowel disease. 2003;4:210-28.
16. Ho S-M, Lewis JD, Mayer EA, Bernstein CN, Plevy SE, Chuang E, et al. Challenges in IBD research: environmental triggers. Inflammatory bowel diseases. 2019;25(Supplement_2):S13-S23.
17. Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta‐analysis. Wiley Online Library; 2015. p. 634-41.
18. Paul J. Gastrointestinal Tract Infections. Disease Causing Microbes: Springer; 2024. p. 149-215.
19. Ellis H. Review of general surgery 1984-85. Postgraduate Medical Journal. 1985;61(721):941.
20. Lapidus A, Bångstad M, Åström M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn’s disease. The American journal of gastroenterology. 1999;94(5):1261-6.
21. Whorwell P, Hawkins R, Dewbury K, Wright R. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Digestive diseases and sciences. 1984;29:930-3.
22. Popper H. Cholestasis. Annual review of medicine. 1968;19(1):39-56.
23. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M-A, Quervain E, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2012:gutjnl-2012-302578.
24. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nature microbiology. 2019;4(2):293-305.
25. Jacobs JP, Goudarzi M, Singh N, Tong M, McHardy IH, Ruegger P, et al. A disease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients. Cellular and molecular gastroenterology and hepatology. 2016;2(6):750-66.
26. Biagioli M, Marchianò S, Carino A, Di Giorgio C, Santucci L, Distrutti E, et al. Bile acids activated receptors in inflammatory bowel disease. Cells. 2021;10(6):1281.
27. Gallagher K, Catesson A, Griffin JL, Holmes E, Williams HR. Metabolomic analysis in inflammatory bowel disease: a systematic review. Journal of Crohn's and Colitis. 2021;15(5):813-26.
28. Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell host & microbe. 2021;29(8):1294-304. e4.
29. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. nature. 2010;464(7285):59-65.
30. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiological reviews. 2010.
31. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837-48.
32. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. Journal of Biological Chemistry. 2006;281(16):11039-49.
33. Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-γ and interfering with the Wnt/β-catenin pathways. Journal of Biological Chemistry. 2010;285(47):36759-67.
34. Long SL, Gahan CG, Joyce SA. Interactions between gut bacteria and bile in health and disease. Molecular aspects of medicine. 2017;56:54-65.
35. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annual review of biochemistry. 2003;72(1):137-74.
36. Arrese M, Trauner M, Sacchiero RJ, Crossman MW, Shneider BL. Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology. 1998;28(4):1081-7.
37. Axelson M, Aly A, Sjövall J. Levels of 7α‐hydroxy‐4‐cholesten‐3‐one in plasma reflect rates of bile acid synthesis in man. FEBS letters. 1988;239(2):324-8.
38. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Current opinion in gastroenterology. 2014;30(3):332.
39. Kurdi P, Kawanishi K, Mizutani K, Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. Journal of bacteriology. 2006;188(5):1979-86.
40. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-63.
41. Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR. Nutrition and inflammatory bowel disease. Gastroenterology Clinics of North America. 1999;28(2):423-43.
42. Cabré E, Gassull MA. Nutrition in inflammatory bowel disease: impact on disease and therapy. Current opinion in gastroenterology. 2001;17(4):342-9.
43. Squirell E. Serum albumin as a measure of inflammation or malnutrition in inflammatory bowel disease: a cross sectional study: Memorial University of Newfoundland; 2021.
44. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Annals of medicine. 2010;42(2):97-114.
45. Gizard E, Ford A, Bronowicki JP, Peyrin‐Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2014;40(1):3-15.
46. Mendes FD, Levy C, Enders FB, Loftus Jr EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Official journal of the American College of Gastroenterology| ACG. 2007;102(2):344-50.
47. Martínez-Domínguez SJ, García-Mateo S, Laredo V, Gargallo-Puyuelo CJ, Gallego Llera B, López de la Cruz J, et al. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers. 2023;15(13):3367.
48. Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. bmj. 2023;380.
49. Sivakrishnan S, Pharm M. Liver disease overview. World Journal of Pharmacy and Pharmaceutical Sciences. 2019;8(1):1385-95.
50. Halliday J, Chapman RW. Extraintestinal Manifestations of Inflammatory Bowel Disease: Primary Sclerosing Cholangitis. Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. 2012:579-600.
51. Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflammatory bowel diseases. 2012;18(12):2225-31.
52. Feagan BG, MacDonald JK. Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane database of systematic reviews. 2012(10).
53. Kondamudi PK, Malayandi R, Eaga C, Aggarwal D. Drugs as causative agents and therapeutic agents in inflammatory bowel disease. Acta Pharmaceutica Sinica B. 2013;3(5):289-96.
54. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology. 1993;104(5):1293-301.
55. Ransford R, Langman M. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536.
56. Baron J, Connell A, Kanaghinis T, Lennard-Jones J, Jones FA. Out-patient treatment of ulcerative colitis. British medical journal. 1962;2(5302):441.
57. FN A. Corticosteroids and immunomodurators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320-7.
58. Fraser AG. Methotrexate: first-line or second-line immunomodulator? European journal of gastroenterology & hepatology. 2003;15(3):225-31.
2. Chen C-H, Lin C-L, Kao C-H. Association between inflammatory bowel disease and cholelithiasis: a nationwide population-based cohort study. International journal of environmental research and public health. 2018;15(3):513.
3. Fagagnini S, Heinrich H, Rossel J-B, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PloS one. 2017;12(10):e0185193.
4. da Silva Gaspar SR, Mendonca T, Oliveira P, Oliveira T, Dias J, Lopes T. Urolithiasis and crohn's disease. Urology annals. 2016;8(3):297.
5. Hegyi P, Maléth J, Walters JR, Hofmann AF, Keely SJ. Guts and gall: bile acids in regulation of intestinal epithelial function in health and disease. Physiological reviews. 2018;98(4):1983-2023.
6. Pereira S, Bain I, Kumar D, Dowling R. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Alimentary pharmacology & therapeutics. 2003;17(7):923-33.
7. Ramos GP, Papadakis KA, editors. Mechanisms of disease: inflammatory bowel diseases. Mayo Clinic Proceedings; 2019: Elsevier.
8. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129(3):827-36.
9. Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Tysk C, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013:gutjnl-2012-303661.
10. KHAN R, PARI B. RISK FACTORS OF GALLBLADDER STONE IN LADY READING HOSPITAL PESHAWAR, PAKISTAN. Quantum Journal of Social Sciences and Humanities. 2023;4(5):195-213.
11. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut and liver. 2012;6(2):172.
12. Krawczyk M, Miquel JF, Stokes CS, Zuniga S, Hampe J, Mittal B, et al. Genetics of biliary lithiasis from an ethnic perspective. Clinics and research in hepatology and gastroenterology. 2013;37(2):119-25.
13. Naeem M, Rahimnajjad NA, Rahimnajjad MK, Khurshid M, Ahmed QJ, Shahid SM, et al. Assessment of characteristics of patients with cholelithiasis from economically deprived rural Karachi, Pakistan. BMC research notes. 2012;5(1):1-8.
14. Aslam HM, Saleem S, Edhi MM, Shaikh HA, Hafiz M, Saleem M. Assessment of gallstone predictor: comparative analysis of ultrasonographic and biochemical parameters. International archives of medicine. 2013;6(1):1-7.
15. Geboes K. Histopathology of Crohn’s disease and ulcerative colitis. Inflammatory bowel disease. 2003;4:210-28.
16. Ho S-M, Lewis JD, Mayer EA, Bernstein CN, Plevy SE, Chuang E, et al. Challenges in IBD research: environmental triggers. Inflammatory bowel diseases. 2019;25(Supplement_2):S13-S23.
17. Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta‐analysis. Wiley Online Library; 2015. p. 634-41.
18. Paul J. Gastrointestinal Tract Infections. Disease Causing Microbes: Springer; 2024. p. 149-215.
19. Ellis H. Review of general surgery 1984-85. Postgraduate Medical Journal. 1985;61(721):941.
20. Lapidus A, Bångstad M, Åström M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn’s disease. The American journal of gastroenterology. 1999;94(5):1261-6.
21. Whorwell P, Hawkins R, Dewbury K, Wright R. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Digestive diseases and sciences. 1984;29:930-3.
22. Popper H. Cholestasis. Annual review of medicine. 1968;19(1):39-56.
23. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M-A, Quervain E, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2012:gutjnl-2012-302578.
24. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nature microbiology. 2019;4(2):293-305.
25. Jacobs JP, Goudarzi M, Singh N, Tong M, McHardy IH, Ruegger P, et al. A disease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients. Cellular and molecular gastroenterology and hepatology. 2016;2(6):750-66.
26. Biagioli M, Marchianò S, Carino A, Di Giorgio C, Santucci L, Distrutti E, et al. Bile acids activated receptors in inflammatory bowel disease. Cells. 2021;10(6):1281.
27. Gallagher K, Catesson A, Griffin JL, Holmes E, Williams HR. Metabolomic analysis in inflammatory bowel disease: a systematic review. Journal of Crohn's and Colitis. 2021;15(5):813-26.
28. Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell host & microbe. 2021;29(8):1294-304. e4.
29. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. nature. 2010;464(7285):59-65.
30. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiological reviews. 2010.
31. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837-48.
32. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. Journal of Biological Chemistry. 2006;281(16):11039-49.
33. Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-γ and interfering with the Wnt/β-catenin pathways. Journal of Biological Chemistry. 2010;285(47):36759-67.
34. Long SL, Gahan CG, Joyce SA. Interactions between gut bacteria and bile in health and disease. Molecular aspects of medicine. 2017;56:54-65.
35. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annual review of biochemistry. 2003;72(1):137-74.
36. Arrese M, Trauner M, Sacchiero RJ, Crossman MW, Shneider BL. Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology. 1998;28(4):1081-7.
37. Axelson M, Aly A, Sjövall J. Levels of 7α‐hydroxy‐4‐cholesten‐3‐one in plasma reflect rates of bile acid synthesis in man. FEBS letters. 1988;239(2):324-8.
38. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Current opinion in gastroenterology. 2014;30(3):332.
39. Kurdi P, Kawanishi K, Mizutani K, Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. Journal of bacteriology. 2006;188(5):1979-86.
40. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-63.
41. Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR. Nutrition and inflammatory bowel disease. Gastroenterology Clinics of North America. 1999;28(2):423-43.
42. Cabré E, Gassull MA. Nutrition in inflammatory bowel disease: impact on disease and therapy. Current opinion in gastroenterology. 2001;17(4):342-9.
43. Squirell E. Serum albumin as a measure of inflammation or malnutrition in inflammatory bowel disease: a cross sectional study: Memorial University of Newfoundland; 2021.
44. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Annals of medicine. 2010;42(2):97-114.
45. Gizard E, Ford A, Bronowicki JP, Peyrin‐Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2014;40(1):3-15.
46. Mendes FD, Levy C, Enders FB, Loftus Jr EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Official journal of the American College of Gastroenterology| ACG. 2007;102(2):344-50.
47. Martínez-Domínguez SJ, García-Mateo S, Laredo V, Gargallo-Puyuelo CJ, Gallego Llera B, López de la Cruz J, et al. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers. 2023;15(13):3367.
48. Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. bmj. 2023;380.
49. Sivakrishnan S, Pharm M. Liver disease overview. World Journal of Pharmacy and Pharmaceutical Sciences. 2019;8(1):1385-95.
50. Halliday J, Chapman RW. Extraintestinal Manifestations of Inflammatory Bowel Disease: Primary Sclerosing Cholangitis. Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. 2012:579-600.
51. Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflammatory bowel diseases. 2012;18(12):2225-31.
52. Feagan BG, MacDonald JK. Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane database of systematic reviews. 2012(10).
53. Kondamudi PK, Malayandi R, Eaga C, Aggarwal D. Drugs as causative agents and therapeutic agents in inflammatory bowel disease. Acta Pharmaceutica Sinica B. 2013;3(5):289-96.
54. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology. 1993;104(5):1293-301.
55. Ransford R, Langman M. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536.
56. Baron J, Connell A, Kanaghinis T, Lennard-Jones J, Jones FA. Out-patient treatment of ulcerative colitis. British medical journal. 1962;2(5302):441.
57. FN A. Corticosteroids and immunomodurators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320-7.
58. Fraser AG. Methotrexate: first-line or second-line immunomodulator? European journal of gastroenterology & hepatology. 2003;15(3):225-31.
Article Sidebar
Published
Jun 29, 2024
Article Details
How to Cite
Dr Shah Nawaz Khatti, Dr Talal Safdar, Dr Saad Inayat Ullah, Dr Asim Shehzad, Dr Fareeha Naseer Syed, & Farah Ali. (2024). RELATIONSHIP BETWEEN INFLAMMATORY BOWEL DISEASE AND CHOLELITHIASIS. Journal of Population Therapeutics and Clinical Pharmacology, 31(6), 3337-3347. https://doi.org/10.53555/zm2ak371
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Dr Shah Nawaz Khatti
Assistant Professor of General Surgery, Liaquat University of Medical and Health Sciences Jamshoro Pakistan
Dr Talal Safdar
Assistant Professor of Medicine, Fauji Foundation Hospital Rawalpindi, Pakistan
Dr Saad Inayat Ullah
Trainee Medical Officer, Surgical B Unit, Hayatabad Medical Complex Peshawar, Pakistan
Dr Asim Shehzad
Assistant Professor, Department of Gastroenterology, Fauji Foundation Hospital Rawalpindi, Punjab, Pakistan
Dr Fareeha Naseer Syed
Assistant Professor of Pathology, Department of Pathology, CMH Multan Institute of Medical Sciences, Multan, Pakistan
Farah Ali
Senior House Officer, Hepato Pancreatico Biliary & Liver Transplant Unit, Shaikh Zayed Hospital Lahore, Pakistan
How to Cite
Dr Shah Nawaz Khatti, Dr Talal Safdar, Dr Saad Inayat Ullah, Dr Asim Shehzad, Dr Fareeha Naseer Syed, & Farah Ali. (2024). RELATIONSHIP BETWEEN INFLAMMATORY BOWEL DISEASE AND CHOLELITHIASIS. Journal of Population Therapeutics and Clinical Pharmacology, 31(6), 3337-3347. https://doi.org/10.53555/zm2ak371